Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;35(1):171-176.
doi: 10.1002/mds.27872. Epub 2019 Sep 30.

Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies

Gesine Respondek  1   2 , Max-Joseph Grimm  1   2 , Ines Piot  1   2 , Thomas Arzberger  3   4 , Yaroslau Compta  5 , Elisabet Englund  6 , Leslie W Ferguson  7 , Ellen Gelpi  8   9 , Sigrun Roeber  4 , Armin Giese  4 , Murray Grossman  10 , David J Irwin  10 , Wassilios G Meissner  11   12   13   14 , Christer Nilsson  6 , Alexander Pantelyat  15 , Alex Rajput  7 , John C van Swieten  16 , Claire Troakes  17 , Günter U Höglinger  1   2   18 ; Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group
Collaborators, Affiliations

Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies

Gesine Respondek et al. Mov Disord. 2020 Jan.

Abstract

Background: The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category "probable 4-repeat (4R)-tauopathy" for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration.

Objectives: To validate the accuracy of these clinical criteria for "probable 4R-tauopathy" to predict underlying 4R-tauopathy pathology.

Methods: Diagnostic accuracy for 4R-tauopathies according to the established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson's disease, multiple system atrophy, and frontotemporal lobar degeneration (grouped as non-4R-tauopathies).

Results: We identified 250 cases with progressive supranuclear palsy (N = 195) and corticobasal degeneration (N = 55) and with and non-4R-tauopathies (N = 161). Sensitivity and specificity of "probable 4R-tauopathy" was 10% and 99% in the first year and 59% and 88% at final record.

Conclusions: The new diagnostic category "probable 4R-tauopathy" showed high specificity and may be suitable for the recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tauopathy. The low sensitivity underpins the need for diagnostic biomarkers. © 2019 International Parkinson and Movement Disorder Society.

Keywords: Four-repeat tauopathies; corticobasal degeneration; diagnostic criteria; progressive supranuclear palsy.

PubMed Disclaimer

References

    1. Höglinger GU. Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No. Mov Disord Clin Pract. 2018;5:141–144. - PMC - PubMed
    1. Höglinger GU, Respondek G, Stamelou M, et al., for the Movement Disorder Society-endorsed PSP Study Group. Clinical Diagnosis of Progressive Supranuclear Palsy - The Movement Disorder Society Criteria. Movement Disorders, 2017;32(6):853–864. - PMC - PubMed
    1. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80: 496–503. - PMC - PubMed
    1. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16:552–563. - PMC - PubMed
    1. Gazzina S, Respondek G, Compta Y, et al. Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration. bioRxiv 2019. January 15. doi:10.1101/520510. [Epub ahead of print] - DOI

Publication types